Cyriac Abby Philips, Rajaguru Paramaguru, Philip Augustine, Sasidharan Rajesh, Rizwan Ahamed, Tom George, Guruprasad Padsalgi – 12 April 2019 – Drug‐induced liver injury (DILI) due to complementary and alternative medicine (CAM) use is on the rise throughout the world by patients looking for “safer” alternatives. However, data on acute‐on‐chronic liver failure (ACLF) due to CAM are lacking. In a large cohort of patients with cirrhosis, we retrospectively studied CAM‐related health‐seeking behavior and attempted to identify those who developed possible CAM‐DILI‐related ACLF.

Min Su You, Woo Hyun Paik, Young Hoon Choi, Bang‐sup Shin, Sang Hyub Lee, Ji Kon Ryu, Yong‐Tae Kim, Kyung‐Suk Suh, Kwang‐Woong Lee, Nam‐Joon Yi, Suk Kyun Hong – 12 April 2019 – Right lobe (RL) living donor liver transplantation (LDLT) usually includes 2 bile duct anastomosis sites, namely, the right anterior and the right posterior segmental ducts. This study aimed to evaluate the optimal treatment for biliary strictures following RL LDLT with respect to unilateral or bilateral drainage techniques.

12 April 2019

12 April 2019

Yuanchang Hu, Chao Yang, Gefengqiang Shen, Shikun Yang, Xuyu Cheng, Feng Cheng, Jianhua Rao, Xuehao Wang – 10 April 2019 – Hyperglycemia aggravates hepatic ischemia/reperfusion injury (IRI), but the underlying mechanism for the aggravation remains elusive. Sphingosine‐1‐phosphate (S1P) and sphingosine‐1‐phosphate receptors (S1PRs) have been implicated in metabolic and inflammatory diseases. Here, we discuss whether and how S1P/S1PRs are involved in hyperglycemia‐related liver IRI.

Elisa Lozano, Rocio I.R. Macias, Maria J. Monte, Maitane Asensio, Sofia Carmen, Laura Sanchez‐Vicente, Marta Alonso‐Peña, Ruba Al‐Abdulla, Patricia Munoz‐Garrido, Letizia Satriano, Colm J. O'Rourke, Jesus M. Banales, Matias A. Avila, Maria L. Martinez‐Chantar, Jesper B. Andersen, Oscar Briz, Jose J.G. Marin – 10 April 2019 – Although the multi‐tyrosine kinase inhibitor sorafenib is useful in the treatment of several cancers, cholangiocarcinoma (CCA) is refractory to this drug.

Paul Martin – 9 April 2019

Agnès Desroches‐Castan, Emmanuelle Tillet, Nicolas Ricard, Marie Ouarné, Christine Mallet, Lucid Belmudes, Yohann Couté, Olivier Boillot, Jean‐Yves Scoazec, Sabine Bailly, Jean‐Jacques Feige – 9 April 2019 – Bone morphogenetic protein 9 (BMP9) is a circulating factor produced by hepatic stellate cells that plays a critical role in vascular quiescence through its endothelial receptor activin receptor‐like kinase 1 (ALK1). Mutations in the gene encoding ALK1 cause hereditary hemorrhagic telangiectasia type 2, a rare genetic disease presenting hepatic vessel malformations.

Sanne Brun Jensen, Ulrik Fahnøe, Long V. Pham, Stéphanie Brigitte Nelly Serre, Qi Tang, Lubna Ghanem, Martin Schou Pedersen, Santseharay Ramirez, Daryl Humes, Anne Finne Pihl, Jonathan Filskov, Christina Søhoel Sølund, Julia Dietz, Slim Fourati, Jean‐Michel Pawlotsky, Christoph Sarrazin, Nina Weis, Kristian Schønning, Henrik Krarup, Jens Bukh, Judith Margarete Gottwein – 9 April 2019 – Protease inhibitors (PIs) are important components of treatment regimens for patients with chronic hepatitis C virus (HCV) infection.

Yong He, Seonghwan Hwang, Yan Cai, Seung‐Jin Kim, Mingjiang Xu, Dingcheng Yang, Adrien Guillot, Dechun Feng, Wonhyo Seo, Xin Hou, Bin Gao – 9 April 2019 – Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of diseases ranging from simple steatosis to more severe forms of liver injury including nonalcoholic steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma (HCC). In humans, only 20%‐40% of patients with fatty liver progress to NASH, and mice fed a high‐fat diet (HFD) develop fatty liver but are resistant to NASH development.